NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT07327164 2026-01-09Precision Medicine for Neurocutaneous Syndromes in Western ChinaWest China HospitalCompleted1,200 enrolled